Dysthymic disorder: treatment with citalopram.
We studied 15 patients with dysthymic disorder with open-label citalopram. The purpose of this study was to determine the dose range and safety of citalopram necessary for treatment of patients with dysthymic disorder and to attempt to increase doses in order to enhance remission of patients with dysthymic disorder when treated. Citalopram was well tolerated. The mean dose used in this 10-week study was 37.3 mg and the majority of patients responded to treatment. Various criteria for response and remission were employed. These findings are intended to give guidelines for a subsequent treatment study of dysthymic patients with citalopram using a double-blind placebo-controlled strategy.
Dunner
David L
DL
Center for Anxiety and Depression, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington 98105, USA.
Hendricksen
Helen E
HE
Bea
Carolyn
C
Budech
Chris B
CB
Friedman
S D
SD
D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000627:therapeutic use*; D015283:Citalopram / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D019263:Dysthymic Disorder / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D008297:Male; D012074:Remission Induction; D011795:Surveys and Questionnaires
D018687:Antidepressive Agents, Second-Generation; D015283:Citalopram